Drug intelligence / Profile preview

ATH03

Development stage: Phase 1
Lead developer: AC Immune
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ATH03 is a vaccine developed by AFFiRiS AG targeting the cholesterol ester transfer protein (CETP). It is designed to induce an immune response against CETP, which plays a key role in lipid metabolism by transferring cholesterol esters from high-density lipoprotein (HDL) to other lipoprotein particles. By inhibiting CETP, ATH03 aims to increase HDL cholesterol levels and potentially reduce the risk of atherosclerosis. The drug has been evaluated in Phase 1 clinical trials for safety, immunogenicity, and dose response in healthy male subjects with low HDL cholesterol concentrations[1][2].

Targets

CETP

Beyond the preview

Go deeper on ATH03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATH03.

Explore the full profile